---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-007894"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:40:27.579736+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte appoints Robert Weinstein to Board, removes cumulative voting

## Summary
- Robert Weinstein appointed to Board on Nov 14, 2022; chairs Audit Committee and will join Nominating Committee if elected at Dec 28, 2022 annual meeting.
- Interim CEO Joshua Silverman's month-to-month employment formalized; monthly salary set at $31,250.
- Bylaw amended to eliminate cumulative voting for directors; elections now decided by plurality vote.
- Board expanded from five to six members effective immediately.

## SEC filing metadata
- accession: 0001683168-22-007894
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822007894/0001683168-22-007894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822007894/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-007894
- JSON: https://secwatch.observer/filing/0001683168-22-007894.json
- Plain text: https://secwatch.observer/filing/0001683168-22-007894.txt

## Key facts
- Executive change
  Robert Weinstein was appointed as Director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 14, 2022, the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) increased the size of the Board to six members and appointed Robert Weinstein to serve as a member of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822007894/0001683168-22-007894-index.htm
- Governance Changes
  PharmaCyte Biotech, Inc.: Removed cumulative voting provision for director elections and replaced with plurality voting (effective 2022-11-14).
  - Change: bylaw amendment
  - Effective: 2022-11-14
  source text: On November 14, 2022, the Board approved an amendment (the “Bylaw Amendment”) to the Company’s bylaws, as amended (the “Bylaws”), effective immediately. Pursuant to the Bylaw Amendment, the provision of the Bylaws allowing for cumulative voting in connection with the election of directors, which was invalid in the Bylaws, was removed and replaced with a provision allowing for the election of directors only by means of a plurality.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822007894/0001683168-22-007894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.